BRIEF—Bayer reveals negative Phase III results for pneumonia program

Germany’s Bayer has announced negative results from the Phase III INHALE program investigating Amikacin Inhale, also known as BAY 41-6551, in combination with standard of care in certain pneumonia patients.

Bayer says the candidate did not demonstrate superiority, with the study failing both the primary and all secondary endpoints.

The program is being developed through a collaboration with Nektar Therapeutics.